Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Bortezomib (Primary)
- Indications Transplant rejection
- Focus Adverse reactions
- Acronyms BORTEJECT
- 22 Mar 2017 Status changed from active, no longer recruiting to completed.
- 03 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 03 Mar 2015 Planned End Date changed from 1 Oct 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.